Monday, August 31, 2026

[WAY – Waystar] Healthcare is a very complicated invoice

Waystar sells revenue-cycle software for a US claims process where roughly 18% of submitted claims are initially denied and healthcare administration consumes 15% to 25% of spending.

WAY $5B

scuttleblurb Aug 31 15 clicks

Aug 29 VEEV $46B

Veeva 2Q’26: “SaaSpocalypse” Cancelled

MBI Deep Dives 17 clicks

Aug 29 MSFT $3.8T

Microsoft ($MSFT) - Deep Dive

Bearhold Research 18 clicks

From X

@ChrisCamillo Aug 31 2 clicks

Chris Camillo on X

Take-Two Interactive, $TTWO, trades weeklies around GTA 6 news and debates the benchmark for the game’s success.

@P_Remarks Aug 31 2 clicks

Prepared Remarks on X

$orcl https://t.co/82tycGZoPl

@RagingVentures Aug 31 2 clicks

Raging Capital Ventures on X

Sol Bier and Factorial Funds backed SPCX, Anthropic, Perplexity and ElevenLabs early. A conference interview covers Sol Bier’s venture investing.

@ChrisCamillo Aug 31 2 clicks

Chris Camillo on X

@reddy67874 @Jerry19880 @piques15 only stock i added to today was $AMZN. like the risk/reward probabilities here on $TTWO, but there’s more downside if player sentiment and engagement data start moving the wrong way.

@leevalueroach Aug 31 3 clicks

Lee Roach on X

@steven_finch Pretty much everything I own has revenues declining. People pissed and moaned when I bought $HOG because it was "dying"

@irbezek Aug 31 2 clicks

Ian Bezek on X

@sigmazerocap I own a small position in $CRM (thankfully lower cost base), and no $META, so $CRM it is. Clicks results. Wow, guess CRM is going up another 25% next quarter. Love when everyone is positioned wrongly.

@ChrisCamillo Aug 31 3 clicks

Chris Camillo on X

@ryanTesling @piques15 added to $AMZN today, no surprise there

@ChrisCamillo Aug 31 2 clicks

Chris Camillo on X

@ryanTesling don’t care as i’m not focused on $AMZN short term trading rn

Meta Buys Away its Distraction at Minimal Cost

Meta’s $18 billion teen-addiction settlement makes $5.3 billion contingent on YouTube and TikTok adopting matching restrictions, while…

META $1.5TRBLX $29B

MBI Deep Dives Aug 28 15 clicks

Making sense of Sandisk’s long-term financial model

Sandisk’s FY28-FY30 model relies on long-term NAND agreements holding near-80% gross-margin floors despite pricing 26-28% below current…

SNDK $227B

Bristlemoon Capital Aug 28 19 clicks

CMCSA 2026-08-28

After A Decade Of Underperformance, Comcast Is Finally Ready To Rebound

CMCSA $95B

Max Greve Aug 28 3 clicks

Late August 2026 Random Ramblings

Higher rates could compress equity multiples and raise AI data center lease costs, while UWMC and Cogent raise questions about CEO-driven…

UWMC $2.4B

Yet Another Value Podcast Aug 27 26 clicks

Nvidia Climbing the Wall of Worries

Nvidia guided FY2028 revenue toward $700 billion, roughly 70% growth, while supply constraints and neocloud demand face concerns over…

NVDA $5.4T

MBI Deep Dives Aug 27 9 clicks

BHVN 2026-08-27

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

BHVN $2.4B

Edmund Ingham Aug 27 5 clicks

Domo (Arigato), for this potential multi-bagger options trade

Domo’s $400 million sale to Progress would leave a cash-rich public shell with $900 million of NOLs; January 2028 $5 calls cost 22 cents.

PRGS $2.1B

Triple S Special Situations Investing Aug 27 7 clicks

[scuttleslops] AI Data Center Economics, ADI, INTU, IDXX

AWS AI campuses cost $40–$45 billion per gigawatt, with Trainium 3 expected to lift compute per megawatt and improve infrastructure returns.

AMZN $2.8T

scuttleblurb Aug 26 9 clicks

KMI 2026-08-26

Kinder Morgan: The Consolidation Is An Opportunity Before The Next Leg Higher

KMI $71B

Steven Fiorillo Aug 26 3 clicks

$ELAL: El Al is a wartime monopoly at 2x EBITDA. Is that a trap? | ASB Partners

El Al trades near 2x EBITDA after wartime near-monopoly profits, with $1.3 billion of net cash and owned aircraft weighed against…

ELALF $3.4B

Yet Another Value Podcast Aug 20 16 clicks

VSEC · long

Vse CORP

VSE Corp trades at $185, with a stated $246 fair value and 2027 estimated EV/EBITDA of 15x.

VSEC $5.6B

Value Investors Club May 30 4 clicks

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2.5B

John Hempton's Newsletter Oct 31 1 click

Does anyone remember when Alnylam went up 50 percent in a day on a phase three result

Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.

ALNY $36B

John Hempton's Newsletter Sep 12 1 click

We can get some extra votes. Pity they are worthless and scumbags are in charge of governance.

Campari’s five-year loyalty plan grants five votes per share, letting its controlling shareholder sell stock while retaining control and…

DVCMY $8.1B

John Hempton's Newsletter Aug 7 1 click

[WAY – Waystar] Healthcare is a very complicated invoice

Veeva 2Q’26: “SaaSpocalypse” Cancelled

Microsoft ($MSFT) - Deep Dive

From X

Chris Camillo on X

Prepared Remarks on X

Raging Capital Ventures on X

Chris Camillo on X

Lee Roach on X

Ian Bezek on X

Chris Camillo on X

Chris Camillo on X

Investor Letters

Meta Buys Away its Distraction at Minimal Cost

Making sense of Sandisk’s long-term financial model

After A Decade Of Underperformance, Comcast Is Finally Ready To Rebound

Late August 2026 Random Ramblings

Nvidia Climbing the Wall of Worries

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Domo (Arigato), for this potential multi-bagger options trade

[scuttleslops] AI Data Center Economics, ADI, INTU, IDXX

Kinder Morgan: The Consolidation Is An Opportunity Before The Next Leg Higher

$ELAL: El Al is a wartime monopoly at 2x EBITDA. Is that a trap? | ASB Partners

Vse CORP

Sarepta Risk and the FDA

Does anyone remember when Alnylam went up 50 percent in a day on a phase three result

We can get some extra votes. Pity they are worthless and scumbags are in charge of governance.

Publications we follow

X accounts we follow

Sectors